Active	Status	Sponsor type	Region	Phase	Filter
6 Active 1 Inactive 7 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes:- Show only changed items Enrollment:

Advanced Filters

6 Trials

Active Trials   

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
Pullarkat, Vinod
NCT04747613: Long-term Safety and Tolerability of Iptacopan in Patients With Paroxysmal Nocturnal Hemoglobinuria	Recruiting	3	250	Europe, Japan, US, RoW	Iptacopan, LNP023	Novartis Pharmaceuticals	Paroxysmal Nocturnal Hemoglobinuria	10/27	10/27
NCT04284228: Antigen-specific T Cell Therapy for AML or MDS Patients With Relapsed Disease After Allo-HCT	Active, not recruiting	1/2	22	US	Infusion of NEXI-001 T Cells	NexImmune Inc.	Acute Myeloid Leukemia (AML), Myelodysplastic Syndrome (MDS)	10/24	03/25
NCT02509546: 8-Chloroadenosine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia	Completed	1/2	20	US	8-Chloroadenosine, 8-Chloro-adenosine, 8-Cl-adenosine, 8-Cl-Ado, Laboratory Biomarker Analysis, Pharmacological Study	City of Hope Medical Center, National Cancer Institute (NCI)	Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome, Recurrent Acute Myeloid Leukemia, Refractory Acute Myeloid Leukemia	03/21	03/21
NCT04810611: Phase Ib Study of Select Drug Combinations in Patients With Lower Risk MDS	Terminated	1	33	Europe, US, RoW	MBG453, sabatolimab, NIS793, canakinumab, ACZ885	Novartis Pharmaceuticals	Myelodysplastic Syndromes	04/24	04/24
NCT04937166: A Study of Dual-SIgnaling Protein 107 (DSP107) for Patients with Hematological Malignancies	Recruiting	1	36	US	DSP107, Azacitidine, Vidaza, Venetoclax, Venclexta, Venclyxto	Kahr Medical	Acute Myeloid Leukemia, Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia	06/25	06/25
NCT05263284: 8-Chloroadenosine in Combination With Venetoclax for the Treatment of Patients With Relapsed/Refractory Acute Myeloid Leukemia	Recruiting	1	30	US	8-Chloroadenosine, 8-Chloro-adenosine, 8-Cl-adenosine, 8-Cl-Ado, Venetoclax, ABT-0199, ABT-199, ABT199, GDC-0199, RG7601, Venclexta, Venclyxto	City of Hope Medical Center, National Cancer Institute (NCI)	Acute Myeloid Leukemia, Recurrent Acute Myeloid Leukemia, Refractory Acute Myeloid Leukemia	01/27	01/27